Warning  Please take our Crypto Currency survey here
London South East Logo | UK Share Price information



Register
Login:
Share:
Email Facebook Twitter




Summit Ther Share Price (SUMM)



Share Price Information for Summit Ther (SUMM)


Share Price: 187.50Bid: 185.00Ask: 190.00Change: 0.00 (0.00%)No Movement on Summit Ther
Spread: 5.00Spread as %: 2.70%Open: 190.00High: 190.00Low: 185.00Yesterday’s Close: 187.50

Summit Therapeutics Plc Ord 1P

Summit Ther is listed in the FTSE AIM All-Share
Summit Ther is part of the Medicine and Biotech Research sector






Share Price SpacerPrice
187.50

Share Price SpacerBid
185.00

Share Price SpacerAsk
190.00

Share Price SpacerChange
0%0.00

Share Price SpacerVolume
121

Share Price SpacerOpen
190.00

Share Price SpacerHigh
190.00

Share Price SpacerLow
185.00

Share Price SpacerClose
187.50

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 70.63m £132.43m 1,500

52 Week High 265.00 52 Week High Date 11-SEP-2017
52 Week Low 140.00 52 Week Low Date 7-NOV-2017

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
2 121 0 -5.357 -35.00 0.00 0.00


London South East Users info for Summit Ther




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

16-Jan-18
15:12:48
185.10
50
Sell* 
185.00
190.00
92.55
Trade Type:
Ordinary

16-Jan-18
09:36:43
185.10
71
Sell* 
185.00
190.00
131.42
Trade Type:
Ordinary

15-Jan-18
16:13:24
185.10
107
Sell* 
185.00
190.00
198.06
Trade Type:
Ordinary




View more Summit Ther trades >>

Directors Deals for Summit Ther (SUMM)
Trade DateActionNotifierPriceCurrencyAmountHolding
18-Jun-15Buy
Trade Notifier Information for Summit Therapeutics
David Wurzer held the position of Non-Executive Director at Summit Therapeutics at the time of this trade.
 David Wurzer
2.33USD7,5007500
17-Jun-15Buy
Trade Notifier Information for Summit Therapeutics
Valerie Andrews held the position of Non-Executive Director at Summit Therapeutics at the time of this trade.
 Valerie Andrews
2.3USD10,50010500
16-Jun-15Buy
Trade Notifier Information for Summit Therapeutics
Frank Armstrong held the position of Non-Executive Chairman at Summit Therapeutics at the time of this trade.
 Frank Armstrong
2.34USD4,25014442
View more Summit Ther directors dealings >>



Date/TimeAuthorSubjectShare PriceOpinion
Fri 09:42gmccRE: NASDAQ moving toward $13 ...180.00No Opinion
Hi everyone , Whatever route the company take , actions taken hopefully will add value to SUMM market cap .

Quite good SUMM have two/three potential pipeline drug assets - not all or nothing company .

Yes getting a bit closer to SUMM decision time as the years fly by , certainly not getting any younger !

Guess we all have our SUMM SP targets in mind personally be very happy to cash in around £3.75 /£4 .

Anyway thought Seeking alpha article fair… Read More
Fri 07:13English_ParisienRE: NASDAQ moving toward $13 ...180.00No Opinion
Morning all,

For me there are still a lot of unknowns that make anticipating outcomes and building a strategy rather challenging:

- whilst we originally thought that DMD was the end goal, suggestions have been made recently of splitting the company in 2 and driving DMD and CDiff (+ new antibiotic projects) separately

- Will Sarepta step up and buy out Summit DMD work ?

- I understood that Summit had wanted to take both projects through to P3 itself, keeping ahold of the US patent… Read More
Thu 21:23ChrisatrdgNASDAQ Close $12.73180.00Strong Buy
NASDAQ closed at $12.73 & equates to £1.89 using 1.35 US$ to the £ - will be interesting to see what happens on AIM Friday.I also agree with AppleMacMan & believe that the NASDAQ is being driven by suggestion of a Serepta take over & recent reports suggesting that Summit on the NASDAQ is a Buy with a forecast of $44 -
https://seekingalpha.com/article/4135902-summit-therapeutics-undervalued-potential-blockbuster-pipeline?
Thu 18:20AppleMacManNASDAQ moving toward $13 ...180.00No Opinion
... looking very good. I've been busy of late and not spent much time here. What opinion do folk have about the wonderful New Year enthusiasm on the NASDAQ?

It's been suggested on other message boards, that this is down to Summit's Discuva deal and clear move toward anti-biotics with RZD already in the bag. I presume that the world can't carry on burying its head in the sand ... one day very soon the value of a search for new anti-biotics has to be made financially viable. The average age… Read More
Wed 18:50Del77RE: Summit Therapeutics: Undervalued180.00No Opinion
The Americans may be starting to see value in Summit with the nasdaq share price over USD 12 on decent volume, up over5%. It would be great to close above USD 12 tonight . D
Wed 15:24English_ParisienRE: Webinar180.00No Opinion
"DMD could be absolutely huge" - Glyn's words
Caveat: he does also note the high-risk stakes involved in the DMD research and high-return potentiel) compared to the lower-risk, lower return CDiff work

I still cannot get yesterday's link to work; computer telling me the page has moved or been deleted ...

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Summit Ther (SUMM) >>

Please login or register to post a message on Share Chat.








Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.